

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

SIGA TECHNOLOGIES INC
Form 8-K
September 27, 2005

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 22, 2005

SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-23047	13-3864870
(State or other jurisdiction of incorporation or organization)	(Commission file number)	(I.R.S. employer identification no.)

420 Lexington Avenue, Suite 408	
New York, New York	10170
(Address of principal executive offices)	(Zip code)

Registrant's telephone number, including area code: (212) 672-9100

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):

-
- ☐ Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On September 22, 2005, SIGA Technologies, Inc., a Delaware corporation ("SIGA"), entered into a \$3.2 million, one-year agreement with the United States Army Medical Research and Material Command ("USAMRMC"). The agreement, for the rapid identification and treatment of anti-viral diseases, is funded through the United States Air Force ("USAF"). SIGA's efforts will aid the USAF Special Operations Command in its use of computational biology to design

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

and develop specific countermeasures against the biological threat agents Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention (CDC) Category A biothreat agent, and Adenovirus is a cause of significant respiratory infectious disease, both of which may impair the combat readiness of USAF Personnel. A copy of the agreement is attached hereto as exhibit 10.1, which is incorporated into this Item 1.01 by reference.

On September 27, 2005, SIGA issued a press release announcing that it had entered into the agreement with USAMRMC. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit No. -----	Description -----
10.1	Agreement, dated as of September 22, 2005, between the United States Army Medical Research and Material Command and SIGA.
99.1	Press Release, dated September 27, 2005.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

Name: Thomas N. Konatich
Title: Chief Financial Officer

Date: September 27, 2005

3